The CNA status and mRNA expression level of ELAVL2 were found to correlate with clinical and molecular features of glioma, and its loss was associated with aggressive MES transition and unfavorable survival rates of GBM patients at all genomic, mRNA, and protein levels. This evidence concerns the gene ELAVL2 and glioblastoma.